Affinergy
Founded Year
2003Stage
Grant | AliveTotal Raised
$7.07MLast Raised
$70K | 7 yrs agoAbout Affinergy
Affinergy develops site-specific biological delivery systems using biofriendly binders that can selectively adhere to proteins, cells and other biomaterial surfaces. Affinergy's multifunctional delivery systems offer unprecedented opportunities to target therapeutic delivery, functionalize medical devices, and enable a variety of diagnostic and biosensor applications. Affinergy is a Duke University spin-out company being incubated by BD (Becton, Dickinson and Company) and is headquartered in Research Triangle Park, NC. IDEA Fund Partners was an investor in the company's Series A financing.
Missing: Affinergy's Product Demo & Case Studies
Promote your product offering to tech buyers.
Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.
Missing: Affinergy's Product & Differentiators
Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).
Expert Collections containing Affinergy
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
Affinergy is included in 2 Expert Collections, including Medical Devices.
Medical Devices
8,633 items
Companies developing medical devices (per the IMDRF's definition of "medical device"). Includes software, lab-developed tests (LDTs), and combination products. *Columns updated as regularly as possible.
Health IT
7,901 items
Affinergy Patents
Affinergy has filed 20 patents.
Application Date | Grant Date | Title | Related Topics | Status |
|---|---|---|---|---|
10/24/2014 | 3/8/2016 | Endocrine system, Human cells, Thyroid, Glands, Adrenal gland | Grant |
Application Date | 10/24/2014 |
|---|---|
Grant Date | 3/8/2016 |
Title | |
Related Topics | Endocrine system, Human cells, Thyroid, Glands, Adrenal gland |
Status | Grant |
Affinergy Frequently Asked Questions (FAQ)
When was Affinergy founded?
Affinergy was founded in 2003.
Where is Affinergy's headquarters?
Affinergy's headquarters is located at 617 Davis Drive, Durham.
What is Affinergy's latest funding round?
Affinergy's latest funding round is Grant.
How much did Affinergy raise?
Affinergy raised a total of $7.07M.
Who are the investors of Affinergy?
Investors of Affinergy include One North Carolina Small Business Program, Charleston Angel Partners, NC IDEA, Trinity Healthcare Development, Wilmington Investor Network and 3 more.
Who are Affinergy's competitors?
Competitors of Affinergy include Integrated Nano-Technologies, Mercator MedSystems, Celsense, ContraVac, Imarad Imaging Systems and 11 more.
Compare Affinergy to Competitors
Rafael Medical has developed a novel anchoring system for safely implanting and retrieving a wide range of intra-vascular devices in a minimally invasive manner. Based on the technology, diagnostic and therapeutic devices can be delivered into small and large blood vessels alike by way of a small-sized delivery system. Following the completion of the SafeFlo Filter the company is now developing additional devices geared to the interventional cardiology market.
ProterixBio develops products to transform the management of chronic diseases.
InPhenix is a developer and manufacturer of optoelectronic devices for the medical, defense, and telecom markets. The company's Super Light Emitting Diodes (SLEDs) are utilized in a variety of optical imaging systems for biomedical applications, and its customers include several leading manufacturers of ophthalmic and laboratory diagnostic instrumentation.
MediGuide is a medical-device company developing tracking and imaging technologies for use during minimally-invasive surgical procedures. Located in Haifa, Israel, MediGuide was established in 2001 as a spin-off of Elbit Systems (NASDAQ: ESLT), a major Israeli defense technology company. MediGuide has developed a highly sophisticated navigation system: Medical Positioning System ("gMPS"), which is aimed to enable real-time tracking of therapeutic and future diagnostic medical devices (gMPS Enabled Devices) such as catheters and stents equipped with miniature gMPS sensors. gMPS is intended to provide clinicians with 3-D information about the structure of the coronary arteries and to track gMPS-enabled devices in these vessels.
Atonomics develops a point of care diagnostic device based on an electro-mechanical concept. This technology changes the way that DNA and antibodies are used in point of care diagnosis.
IMMCO Diagnostics provides high-quality diagnostic test kits and lab testing services worldwide for the screening of autoimmune disorders. IMMCO Diagnostics incorporates working on research, clinical laboratory expertise, and medical devices into an approach to autoimmune diagnostics.
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.